StocksFundsScreenerSectorsWatchlists
EDIT

EDIT - Editas Medicine Inc Stock Price, Fair Value and News

5.50USD-0.05 (-0.90%)Market Closed

Market Summary

EDIT
USD5.50-0.05
Market Closed
-0.90%

EDIT Stock Price

View Fullscreen

EDIT RSI Chart

EDIT Valuation

Market Cap

454.1M

Price/Earnings (Trailing)

-2.96

Price/Sales (Trailing)

5.81

Price/Free Cashflow

-3.32

EDIT Price/Sales (Trailing)

EDIT Profitability

Return on Equity

-43.89%

Return on Assets

-30.7%

Free Cashflow Yield

-30.15%

EDIT Fundamentals

EDIT Revenue

Revenue (TTM)

78.1M

Rev. Growth (Yr)

818.74%

Rev. Growth (Qtr)

1.0K%

EDIT Earnings

Earnings (TTM)

-153.2M

Earnings Growth (Yr)

68.93%

Earnings Growth (Qtr)

58.08%

Breaking Down EDIT Revenue

Last 7 days

-15.8%

Last 30 days

-28.5%

Last 90 days

-31.5%

Trailing 12 Months

-31.5%

How does EDIT drawdown profile look like?

EDIT Financial Health

Current Ratio

5.39

EDIT Investor Care

Shares Dilution (1Y)

18.62%

Diluted EPS (TTM)

-2.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202322.8M19.3M24.6M78.1M
202225.8M31.8M25.6M19.7M
202191.5M81.1M24.5M25.5M
202024.2M32.6M91.6M90.7M
201930.1M25.0M14.4M20.5M
201817.0M21.2M29.5M31.9M
20175.9M5.6M11.0M13.7M
20162.4M5.7M5.9M6.1M
20150001.6M

Tracking the Latest Insider Buys and Sells of Editas Medicine Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 05, 2024
o'neill gilmore neil
sold
-732,884
9.4172
-77,824
ceo
Mar 04, 2024
mei baisong
sold
-191,425
9.4173
-20,327
svp, chief medical officer
Mar 02, 2024
lucera erick
acquired
-
-
61,266
evp, chief financial officer
Mar 02, 2024
burkly linda
acquired
-
-
39,855
evp, chief scientific officer
Mar 02, 2024
o'neill gilmore neil
acquired
-
-
275,125
ceo
Mar 02, 2024
mei baisong
acquired
-
-
89,815
svp, chief medical officer
Dec 05, 2023
eaton bruce
sold
-1,122
10.8972
-103
evp, cbo and cto
Nov 14, 2023
eaton bruce
sold
-5,705
8.2096
-695
evp, cbo and cto
Nov 07, 2023
eaton bruce
sold
-1,167
8.4
-139
evp, cbo and cto
Sep 06, 2023
eaton bruce
sold
-908
8.82
-103
evp, cbo and cto

1–10 of 50

Which funds bought or sold EDIT recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 18, 2024
STATE OF MICHIGAN RETIREMENT SYSTEM
unchanged
-
-741,784
2,031,010
0.01%
Apr 18, 2024
Koss-Olinger Consulting, LLC
sold off
-100
-101,000
-
-%
Apr 16, 2024
Thrive Wealth Management, LLC
unchanged
-
-50,135
137,270
0.03%
Apr 16, 2024
TSFG, LLC
sold off
-100
-1,000
-
-%
Apr 16, 2024
Ameliora Wealth Management Ltd.
unchanged
-
-1,355
3,710
-%
Apr 16, 2024
VOISARD ASSET MANAGEMENT GROUP, INC.
unchanged
-
-271
742
-%
Apr 16, 2024
MCF Advisors LLC
new
-
82.00
82.00
-%
Apr 16, 2024
Register Financial Advisors LLC
new
-
742
742
-%
Apr 15, 2024
Sound Income Strategies, LLC
unchanged
-
-407
1,113
-%
Apr 12, 2024
Westend Capital Management, LLC
sold off
-
-
-
-%

1–10 of 45

Are Funds Buying or Selling EDIT?

Are funds buying EDIT calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own EDIT
No. of Funds

Unveiling Editas Medicine Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 10, 2024
state street corp
10.71%
8,760,151
SC 13G/A
Feb 14, 2024
deep track capital, lp
6.70%
5,473,086
SC 13G/A
Feb 13, 2024
vanguard group inc
10.36%
8,461,701
SC 13G/A
Jan 24, 2024
blackrock inc.
9.6%
7,838,969
SC 13G/A
Jan 10, 2024
state street corp
6.21%
5,069,543
SC 13G/A
Aug 04, 2023
deep track capital, lp
5.51%
4,493,416
SC 13G
Feb 09, 2023
vanguard group inc
10.00%
6,873,123
SC 13G/A
Feb 03, 2023
state street corp
13.41%
9,222,236
SC 13G/A
Jan 26, 2023
blackrock inc.
10.7%
7,338,742
SC 13G/A
Jan 20, 2023
blackrock inc.
10.7%
7,338,742
SC 13G/A

Recent SEC filings of Editas Medicine Inc

View All Filings
Date Filed Form Type Document
Apr 16, 2024
DEFA14A
DEFA14A
Apr 16, 2024
DEF 14A
DEF 14A
Apr 10, 2024
SC 13G/A
Major Ownership Report
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 04, 2024
144
Notice of Insider Sale Intent
Feb 28, 2024
S-8
Employee Benefits Plan
Feb 28, 2024
S-3ASR
S-3ASR

Peers (Alternatives to Editas Medicine Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.0B
6.8B
-2.93% -28.56%
-8.27
5.69
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.3B
1.8B
-2.14% -28.32%
-41.48
9.99
76.23% 61.08%
17.0B
2.4B
5.64% -9.07%
101.38
7.03
15.42% 18.43%
11.9B
3.7B
-9.46% -28.45%
19.84
3.21
8.87% 75.42%
MID-CAP
5.7B
396.6M
-16.55% -42.15%
-10.84
14.45
425.83% 18.94%
4.4B
-
-12.14% 49.76%
-6.72
60.35
54.84% -34.79%
3.1B
270.6M
-14.48% -8.88%
-13.01
11.51
440.80% -27.84%
2.8B
726.4M
-8.72% -14.74%
-45.89
3.87
40.45% 71.62%
2.8B
240.7M
-18.65% -25.84%
-9.44
12.18
-1.03% -92.09%
SMALL-CAP
1.8B
398.2M
-6.41% -11.48%
25.32
4.54
85.90% -14.05%
544.4M
983.7M
-21.26% -56.58%
-1
0.55
-50.36% 17.16%
382.8M
881.7K
-14.69% 262.26%
-8.58
466.16
-77.61% -5.33%
238.4M
4.9M
-4.49% -3.41%
-1.76
48.98
-54.97% 51.71%
6.2M
2.1M
67.92% 36.92%
-0.23
2.14
-13.45% 66.37%

Editas Medicine Inc News

Latest updates
MarketBeat15 Apr 202408:01 pm
Yahoo Finance05 Mar 202408:00 am
The Motley Fool6 months ago

Editas Medicine Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue1025.4%60.005.003.0010.007.000.006.007.0012.006.000.006.0011.0063.0011.006.0012.004.002.002.006.00
Operating Expenses51.4%84.0055.0047.0061.0070.0058.0061.0058.0054.0045.0056.0063.0077.0054.0042.0052.0052.0038.0038.0033.0032.00
  S&GA Expenses-3.5%14.0015.0017.0023.0018.0016.0017.0020.0017.0016.0022.0021.0016.0020.0014.0018.0017.0016.0014.0017.0013.00
  R&D Expenses71.7%70.0041.0030.0038.0052.0041.0044.0038.0038.0029.0034.0042.0062.0034.0028.0035.0035.0023.0024.0016.0019.00
Net Income58.1%-18.87-45.02-40.29-49.04-60.74-55.73-53.45-50.51-41.44-39.08-55.26-56.73-62.508.00-23.57-37.72-37.77-32.94-33.79-29.25-25.05
Net Income Margin75.3%-1.96*-7.93*-10.65*-9.61*-11.18*-7.84*-5.80*-7.22*-7.54*-8.72*-2.05*-1.48*---------
Free Cashflow34.0%-23.55-35.70-40.04-37.61-42.90-48.62-38.48-51.47-37.43-43.13-41.66-49.56---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-1.1%499505542464514531581623677717756780573597655467509372356379420
  Current Assets-5.0%341359441324357427461497507568616632419507610425464339324347375
    Cash Equivalents49.8%12483.00221129142215173215207264342359144283490235240106212160136
  Net PPE4.1%12.0012.0013.0013.0016.0015.0016.0017.0017.0016.0015.0014.0014.0014.0013.0012.0011.0010.009.008.0040.00
Liabilities4.1%150144142147154116115110124130143142179156229232246162163162184
  Current Liabilities7.9%63.0059.0055.0057.0060.0042.0036.0037.0047.0051.0066.0064.0058.0055.0068.0069.0060.0067.0073.0041.0036.00
Shareholder's Equity-3.2%349360400317361415465513554587613638394441427235262210193217236
  Retained Earnings1.0%-1,200-1,212-1,200-1,127-1,078-1,017-961-908-857-816-777-721-665-602-610-586-549-511-478-444-416
  Additional Paid-In Capital0.4%1,5801,5741,5701,4471,4421,4361,4301,4231,4121,4031,3911,3601,0591,0441,037821812721672662652
Shares Outstanding0.1%82.0082.0082.0069.0069.0069.0069.0068.0068.0068.0068.0066.00---------
Float---671---634---1,147---1,840---1,222--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations37.3%-22,240-35,459-38,711-35,768-42,273-48,004-37,845-49,227-34,582-40,785-38,957-49,479-40,100-54,801-30,856-54,08641,024-26,884-25,806-29,0031,327
  Share Based Compensation13.0%5,3454,7315,2154,5075,3645,8816,61811,4317,65710,01213,52612,2045,6735,8465,4176,2206,3366,5596,4937,8556,347
Cashflow From Investing161.1%62,840-102,82012,98223,267-27,52889,227-4,00256,371-22,840-39,6614,7913,244-108,894-152,26574,17346,4647,818-122,30276,11050,626-8,604
Cashflow From Financing-514---61980.003672181,0572,49617,082261,4719,100822211,1533,04784,56943,3532,3691,53330,352

EDIT Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Collaboration and other research and development revenues$ 78,123$ 19,712$ 25,544
Revenue typeService [Member]Service [Member]Service [Member]
Operating expenses:   
Research and development$ 177,651$ 174,958$ 142,507
General and administrative69,65370,70476,183
Total operating expenses247,304245,662218,690
Operating loss(169,181)(225,950)(193,146)
Other income, net:   
Other income, net(1,604)037
Interest income, net17,5665,518607
Total other income, net15,9625,518644
Net loss$ (153,219)$ (220,432)$ (192,502)
Net loss per share, basic (in dollars per share)$ (2.02)$ (3.21)$ (2.85)
Net loss per share, diluted (in dollars per share)$ (2.02)$ (3.21)$ (2.85)
Weighted-average common shares outstanding, basic (in shares)75,965,63368,664,82267,619,388
Weighted-average common shares outstanding, diluted (in shares)75,965,63368,664,82267,619,388

EDIT Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 123,652$ 141,522
Marketable securities199,459202,752
Accounts receivable10,1875,145
Prepaid expenses and other current assets7,5317,335
Total current assets340,829356,754
Marketable securities104,02493,097
Property and equipment, net12,03215,569
Right-of-use assets33,68043,648
Restricted cash and other non-current assets8,5885,253
Total assets499,153514,321
Current liabilities:  
Accounts payable8,2699,511
Accrued expenses34,56331,296
Deferred revenue, current8,2218,221
Operating lease liabilities12,16411,082
Total current liabilities63,21760,110
Operating lease liabilities, net of current portion24,37232,864
Deferred revenue, net of current portion60,66760,667
Other non-current liabilities1,8000
Total liabilities150,056153,641
Stockholders’ equity  
Preferred stock, $0.0001 par value per share: 5,000,000 shares authorized; no shares issued or outstanding00
Common stock, $0.0001 par value per share: 195,000,000 shares authorized; 81,767,263 and 68,847,382 shares issued, and 81,767,263 and 68,847,382 shares outstanding at December 31, 2023 and December 31, 2022, respectively87
Additional paid-in capital1,580,2411,442,405
Accumulated other comprehensive income (loss)198(3,601)
Accumulated deficit(1,231,350)(1,078,131)
Total stockholders’ equity349,097360,680
Total liabilities and stockholders’ equity$ 499,153$ 514,321
EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis 10; autosomal dominant retinitis pigmentosa; and EDIT-301, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
 CEO
 WEBSITEeditasmedicine.com
 INDUSTRYBiotechnology
 EMPLOYEES226

Editas Medicine Inc Frequently Asked Questions


What is the ticker symbol for Editas Medicine Inc? What does EDIT stand for in stocks?

EDIT is the stock ticker symbol of Editas Medicine Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Editas Medicine Inc (EDIT)?

As of Thu Apr 18 2024, market cap of Editas Medicine Inc is 454.07 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers.

What is the fair value of EDIT stock?

You can check EDIT's fair value in chart for subscribers. The fair value of Editas Medicine Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Editas Medicine Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EDIT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Editas Medicine Inc a good stock to buy?

The fair value guage provides a quick view whether EDIT is over valued or under valued. Whether Editas Medicine Inc is cheap or expensive depends on the assumptions which impact Editas Medicine Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EDIT.

What is Editas Medicine Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 18 2024, EDIT's PE ratio (Price to Earnings) is -2.96 and Price to Sales (PS) ratio is 5.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EDIT PE ratio will change depending on the future growth rate expectations of investors.